SSAO Inhibitor (PXS-4728)
Novel SSAO/VAP-1 inhibitor PXS-4728 (formerly known as BI 1467335) - for the treatment of inflammation
PXS-4728 is a very potent and highly selective compound. It is a first-in-class, mechanism-based inhibitor of Semicarbazide-Sensitive Amine Oxidase (SSAO), also known as Vascular Adhesion Protein-1 (VAP-1), or Amine Oxidase Copper Containing 3 (AOC3), PXS-4728 and provides greater than 90% inhibition of its target enzyme for 24 hours after a single oral dose.
PXS-4728 is efficacious in various pre-clinical NASH and lung inflammation models. The inhibition of SSAO can be easily measured with biomarkers and exhibits therapeutic potential across a range of chronic inflammatory conditions.
PXS-4728 was sold to Boehringer Ingelheim (BI) in 2015, initially to develop for the treatment of the liver-related disease Nonalcoholic Steatohepatitis (NASH) and subsequently for diabetic retinopathy (DR). Under the sale agreement Boehringer was responsible for all development, regulatory, manufacturing and commercialisation activities with milestone and other payments to Pharmaxis in relation to the development and approval of PXS-4728 in two indications. Pharmaxis received an upfront payment of €27.5 million (approximately A$39m) and a further €28 upon commencement of phase 2a clinical trials in NASH and DR - a total of A$83 million received from BI over the five years of its development program. The program was discontinued by BI in September 2020 primarily because of the risk of dose dependent drug interactions of the compound identified in a separate Phase I study.
The full program as developed by BI was returned to Pharmaxis in Q1 2021, including the extensive preclinical, clinical, safety and regulatory work carried out by BI. Further analysis of the data package by Pharmaxis scientists has uncovered some potential in neuro inflammatory where the clinical benefits would not be impacted by the BI findings that caused them to discontinue development. Pharmaxis is in discussion with independent investigators and potential partners in relation to neuro inflammatory indications, study protocol design and funding options including grants.
|Description||Phase 2a NASH study|
|Sites||USA, Canada, The Netherlands|
|Description||Phase 2a Study in Diabetic Retinopathy|
|Sites||Austria, Greece, Italy, Norway, Portugal, Spain, United Kingdom, United States|
* ClinicalTrials.gov is a service provided by the U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine. ClinicalTrials.gov provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions. Pharmaxis chooses to publish all Pivotal Trials on the ClinicalTrials.gov website.